Effective intraocular drug delivery poses a major challenge due to the presence of various
elimination mechanisms and physiological barriers that result in low ocular bioavailability …

Eye is the unique sense organ with complex and sophisticated anatomy and physiology.
Being most instrumental for vision, it is secured by varied protective barriers; ranging from …

The low bioavailability and side effects of conventional drugs for eye disease necessitate the
development of efficient drug delivery systems. Accompanying the developments of …

The eye is a distinctive organ with protective anatomy and physiology. Several
pharmacokinetics compartment models of ocular drug delivery have been developed for …

Diseases that affect the eye, including photoreceptor degeneration, diabetic retinopathy, and
glaucoma, affect 11.8 million people in the US, resulting in vision loss and blindness. Loss of …

The impact of proteins and peptides on the treatment of various conditions including ocular
diseases over the past few decades has been advanced by substantial breakthroughs in …

Gene therapy is becoming an influential part of the rapidly increasing armamentarium of
biopharmaceuticals for improving health and combating diseases. Currently, three gene …

Mutations in the gene BEST1 are causally associated with as many as five clinically distinct
retinal degenerative diseases, which are collectively referred to as the “bestrophinopathies” …

Retinoblastoma is lethal by metastasis if left untreated, so the primary goal of therapy is to
preserve life, with ocular survival, visual preservation and quality of life as secondary aims …

Diabetes mellitus, an incurable metabolic disease, is characterized by changes in the
homeostasis of blood sugar levels, being the subcutaneous injection of insulin the first line …